GliXogen Therapeutics ^{For Profit}

GliXogen Therapeutics is a biopharmaceutical company developing a treatment to enhance remyelination in neurodegenerative disorders. All currently available approved medications for MS patients target the immune system and modulate it in a variety of ways, but they are unable to address the neurological damage that existed prior to the diagnosis. The progression of 75% of relapsing-remitting MS patients to the secondary progressive, more severe form of the disease is at least partially attributed to demyelination.